Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: A systematic review

Virology Journal

Volumn 7, Issue , 2010, Pages

  Zhao, Shushan ^a   Tang, Lanhua ^a   Fan, Xuegong ^a   Chen, Lizhang ^a,b   Zhou, Rongrong ^a   Dai, Xiahong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; ANTIVIRUS AGENT; NUCLEOSIDE; PYRIMIDINONE DERIVATIVE;

CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; DRUG EFFICACY; EMBASE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MEDLINE; META ANALYSIS; REVIEW; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; NUCLEOSIDES; PYRIMIDINONES; TREATMENT OUTCOME;

EID: 77956467204     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-211     Document Type: Review

References (23)

1. Hepatitis B today. M Safioleas NJ Lygidakis C Manti, Hepatogastroenterology 2007 54 545 548 17523319
2. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. GA Poland RM Jacobson, N Engl J Med 2004 351 2832 2838 10.1056/NEJMcp041507 15625334
3. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. JF Perz GL Armstrong LA Farrington YJ Hutin BP Bell, J Hepatol 2006 45 529 538 10.1016/j.jhep.2006.05. 013 16879891
4. Telbivudine in the treatment of chronic hepatitis B. K Nash, Adv Ther 2009 26 155 169 10.1007/s12325-009-0004-y 19225726
5. Antiviral L-nucleosides specific for hepatitis B virus infection. ML Bryant EG Bridges L Placidi A Faraj AG Loi C Pierra D Dukhan G Gosselin JL Imbach B Hernandez, et al. Antimicrob Agents Chemother 2001 45 229 235 10.1128/AAC.45.1.229-235.2001 11120971 (Pubitemid 32039120)
6. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. CL Lai N Leung EK Teo M Tong F Wong HW Hann S Han T Poynard M Myers G Chao, et al. Gastroenterology 2005 129 528 536 16083710 (Pubitemid 41096641)
7. Telbivudine versus lamivudine in patients with chronic hepatitis B. CL Lai E Gane YF Liaw CW Hsu S Thongsawat Y Wang Y Chen EJ Heathcote J Rasenack N Bzowej, et al. N Engl J Med 2007 357 2576 2588 10.1056/NEJMoa066422 18094378
8. Clinical Study on Telbivudine Treating Chronic Hepatitis B. DC Tang DM Xie JJ Xu JY He LH Yao ZZ Yang YF Li, Journal of Zhejiang University of Traditional Chinese Medicine 2009 33 214 215
9. Therapeutic effect of 48 weeks of telbivudine on HBeAg-positive chronic hepatitis B. SX Chen XZ Hu F Zhu B Wan P Liu, Infect Dis Info 2009 22 216 218
10. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. J Hou YK Yin D Xu D Tan J Niu X Zhou Y Wang L Zhu Y He H Ren, et al. Hepatology 2008 47 447 454 10.1002/hep.22075 18080339
11. The study of efficacy and side effects of telbivudine and lamivudine for treatment of patients with chronic hepatitis B. XH Zhong Y Liu C Xu LM Xu M Wang MZ Li, Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2009 19 19 21
12. Assessing the quality of reports of randomized clinical trials: is blinding necessary? AR Jadad RA Moore D Carroll C Jenkinson DJ Reynolds DJ Gavaghan HJ McQuay, Control Clin Trials 1996 17 1 12 10.1016/0197-2456(95)00134- 4 8721797
13. Efficacy and its influent factors of telbivudine or lamivudine treated with chronic hepatitis B patients. W Cai, Shanghai Jiao Tong University school of medicine 2009
14. A comparison of curative effect between telbivudine and lamivudine in patients with chronic hepatitis B virus. JN Yang, Chin J Prim Med Pharm 2009 16 1193 1194
15. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. YF Liaw E Gane N Leung S Zeuzem Y Wang CL Lai EJ Heathcote M Manns N Bzowej J Niu, et al. Gastroenterology 2009 136 486 495 10.1053/j.gastro.2008.10.026 19027013
16. Two-year results of a phase III comparative trial of telbivudine vs lamivudine in chinese patients. JD Jia JL Hou YK Yin DZ Xu D Tan J Niu XQ Zhou Y Wang L Zhu N Brown, Journal of Hepatology 2007 46 189 S189 10.1016/S0168- 8278(07)62095-9
17. Efficacy of telbivudine vs lamivudine at 2 years in patinents with HbeAg-positive chronic hepatitis B who are eligible for treatment based on guidelines. J Rasenack T Poynard CL Lai E Gane NA Brown J Heathcote, Journal of Hepatology 2007 46 195 S195 10.1016/S0168-8278(07)62111-4
18. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. D Lavanchy, J Viral Hepat 2004 11 97 107 10.1046/j.1365-2893.2003.00487.x 14996343
19. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. YF Liaw, J Hepatol 2009 51 403 410 10.1016/j.jhep.2009.04.003 19467727
20. Systematic reviews in health care: Assessing the quality of controlled clinical trials. P Juni DG Altman M Egger, BMJ 2001 323 42 46 10.1136/bmj.323.7303.42 11440947
21. Selection and bias - two hostile brothers. P Bauer F Koenig W Brannath M Posch, Stat Med 2010 29 1 13 19844944
22. Publication bias in meta-analysis: its causes and consequences. A Thornton P Lee, J Clin Epidemiol 2000 53 207 216 10.1016/S0895-4356(99)00161-4 10729693
23. Language bias in randomised controlled trials published in English and German. M Egger T Zellweger-Zahner M Schneider C Junker C Lengeler G Antes, Lancet 1997 350 326 329 10.1016/S0140-6736(97)02419-7 9251637